Source comparison
Central Versus Peripheral: The Blood-Brain Barrier Question
A recurring and honestly-contested question in the MT-II literature is whether the peptide’s appetite effect requires it to reach the brain, or whether peripheral administration — the route relevant to real-world use — can produce anorexia on its own. This is
This comparison does not assign a generated winner or score.
- A recurring and honestly-contested question in the MT-II literature is whether the peptide’s appetite effect requires it to reach the brain, or whether peripheral administration — the route relevant to real-world use — can produce anorexia on its own. This is not a pedantic distinction; it determines whether findings from ICV experiments have any bearing on what happens when the compound is injected subcutaneously.
- Trivedi and colleagues addressed the site of anorectic action of peripherally administered MT-II directly. Studying intravenous delivery in rats, they found that peripheral MT-II could suppress feeding, and they set out to determine whether this required brain penetration.5 The general picture that emerges from this and related work is that MT-II given peripherally can access appetite-relevant sites — likely including circumventricular regions and the caudal brainstem where the blood-brain barrier is relatively permeable, as well as some penetration into the CNS — but that central delivery is far more potent per unit dose. In other words, the anorectic effect is real from the periphery but is fundamentally a central-melanocortin phenomenon; the periphery is simply a less efficient route to the same receptors.
- The interpretive caution here is substantial. Peripheral studies are the most externally relevant to how the compound is actually (mis)used, yet they are also the hardest to interpret cleanly, because a systemically distributed nonselective agonist engages MC1R in the skin, MC4R in the cardiovascular system, and MC3R/MC4R in the brain all at once. Some fraction of a peripheral “appetite” effect could in principle reflect nausea or cardiovascular activation rather than pure central satiety. This is one reason the field trusts the central microinjection work more than the peripheral work for mechanistic claims: the closer the delivery is to the target receptor, the smaller the space for confounds. It is also a reason to be skeptical of extrapolating from a clean ICV result to a prediction about what a subcutaneous injection does to a whole organism.